New pill aims to cut dangerous COPD attacks in half
NCT ID NCT07349524
First seen Jan 21, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This study tests an experimental tablet called RSS0343 in people with chronic obstructive pulmonary disease (COPD). The goal is to see if it can safely reduce the number of moderate or severe flare-ups over 48 weeks. About 237 adults aged 40–80 with COPD will take either the drug or a placebo. This is a phase II trial, so it is still early, but results may lead to better daily control of COPD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, 510140, China
Contact
Conditions
Explore the condition pages connected to this study.